Prior Authorization Form Growth Hormone



Fax this form to: 1-800-424-3260 A fax cover sheet is not required.

	ES
MEMBER INFORMATION	
Member's Last Name:	Member's First Name:
Member's Identification Number:	Date of Birth:
PRESCRIBER INFORMATION	
Prescriber's Last Name:	Prescriber's First Name:
National Provider Identifier (NPI) Number:	DEA Number:
Office Phone Number:	Office Fax Number:
CLINICAL CRITERIA	
·	(recent clinical notes, growth charts, lab results, and
growth hormone stimulations test report).	
1. What medication is being requested?	
Yes No	clinical reason the member cannot use the preferred agent?

Page 1 of 4

Revision Date: 01/01/2021

Prior Authorization Form: Growth Hormone

Member's Last Name:									Member's First Name:													
3.	Wh	at is tl	ne diag	nosis	for th	ne m	edica	ation	?		l L			l								
	Growth hormone deficiency (GHD) – pediatric																					
	=		for ges				•	•	•													
		Prade	r-Willi s	syndro	ome -	– ped	diatri	ic														
		Noon	an synd	Irome	– pe	diatr	ric															
		Childh	nood or	ıset gı	rowth	h hor	mon	ie de	ficie	ncy ·	– a	dult										
		Turne	r syndr	ome -	- ped	liatri	С															
		Chron	ic rena	l insuf	ficie	ncy v	vith a	assoc	iate	d gr	owt	th ret	ardati	on –	ped	iatric						
	Panhypopituitarism, iatrogenic pituitary disorder, pituitary tumor, idiopathic short stature – pediatric Adult onset evidence of hypothalamic-pituitary disease or history of cranial irradiation – adult															ric						
		Adult	onset e	eviden	ice of	f hyp	otha	lami	c-pit	uita	ry c	diseas	se or h	istor	y of	crania	al irra	diatio	n – a	dult		
	Other:															_						
For	For Pediatric Members:																					
1.																						
	Yes No																					
2.	Does the member have open bony epiphyses?																					
		Yes	N	0																		
3.	Wh	at is tl	he men	nber's	bon	e age	e and	l the	date	of t	he	stud	y?									
4.	Is th	ne bor	ne age I	ess th	an th	ne m	emb	er's c	hror	nolo	gica	al age	?									
		Yes	N	0																		
5.	Wh	at are	the me	ember	's cu	rren	t heig	ght a	nd w	eigh/	nt?											
6.			mber's	_	t less	s tha	n the	5th	perc	enti	ile f	for ch	ronol	ogica	l age	?						
		Yes	N			_			_	_									_			_
7.			mber's	weigh	nt or	leng	th m	ore t	han :	2 sta	and	lard c	leviati	ons (SD) I	below	the r	nean	for g	estat	iona	
	age	؛ Yes	Пи	•																		
Q			nember		1 +0 r	oach	cato	h_un	aro	wth	hv	200 /	10									
ο.		Yes	N		וטוג	Caci	catt	JII-up	gio	VV LII	IJy	age -	+:									
9			۱۰ mber's		th ve	locit	v les	s thai	n the	10t	th r	nerce	ntile?	Plead	se nr	ovide	grow	rth ch	art			
٥.		Yes	N \square	_		10010	, 100	o ciria.			Þ	JC1 CC	······································	· ·cus	,с р.	Ovide	6.01	CI : CI :	ıaı c.			
10.			membe		e sev	ere :	grow	th re	tard	atio	n w	vith h	eight	more	tha	n 3 S[) belo	w the	e mea	an fo	r	
			gical ag				J						J									
		Yes	□ N	0																		
(Fo	rm c	contin	ued on	next p	oage.)																

© 2016–2021, Magellan Health, Inc. All rights reserved.

Magellan Rx Management – Commercial Clients Revision Date: 01/01/2021 Page 2 of 4

MHID: MRXCOM03_01

Prior Authorization Form: Growth Hormone

Member's Last Name:								Member's First Name:														
11.	Does	the i	memb	er hav	e mo	derate	e grow	th re	tard	_ atio	on wi	ith he	eight	betw	/een	2 an	d 3 9	SD be	low	the n	nean	for
							ecrease															
	Ye	S	□ N	О																		
12.	Is the	mer	nber p	repub	ertal	?																
	Ye	S	□ N	lo																		
13.	Has th	ne m	embe	r's gro	wth v	elocit	ty beer	n mea	asure	ed o	over	1 yea	ar pri	or to	ther	ару	initia	ation	and	was i	t fou	nd
	to be	2 or	more	SD bel	low th	ne me	ean for	age a	and :	sex	?											
	Ye	S	N	lo																		
14.							umente									_			rmor	ne va	lue o	f
					er GH	stim	ulation) as (dete	rmi	ned	by st	anda	rdize	d lab	test	ing?)				
	Ye		∐ N																			
15.					•	•	alamic	•	•				_	•		lforn	natio	on, tu	ımor	, or		
					ciency	/ in at	t least o	one a	iaait	ion	aı pıt	tuitar	y no	rmon	e?							
	Ye	S	∐ N	0																		
For	Turne	r Sy	ndron	ne:																		
16.	Has th	ne di	agnos	is beer	n conf	firme	d by ch	rom	oson	ne a	analy	/sis?										
	Ye	S	N	lo																		
For	GHD A	Asso	ciated	with	Chror	nic Re	enal Ins	uffic	ienc	y:												
17.	Does t	the i	memb	er hav	e chr	onic r	enal in	suffic	ciend	cy?												
	Ye	S	□ N	lo																		
For	Short	Stat	ture H	omeol	box G	ene ((SHOX)	Defi	cien	cy:												
						_	d by ge			-)											
	Ye	S	N	lo																		
For	· Pedia	atrio	: Men	nbers	Rene	wal:																
							ny epip	hvse	s?													
	∏Ye		\square N		•		,	,														
2.	Is the	heig	ht vel	ocity 2	cm/y	year c	over th	e pre	viou	ıs uı	ntrea	ated i	rate?	? Prov	ide (docu	men	tatio	n.			
	Ye	s	N	lo																		
3.	Has th	ne ch	nild rea	ached	the 2	5th pe	ercenti	le of	nori	mal	adu	lt hei	ght?	Prov	ide d	locui	men [.]	tatio	า.			
	Ye	S	\square N	О																		
4.	Is seru	ım iı	nsulin-	like gr	owth	facto	or (IGF-	1) be	eing i	moi	nitor	ed ar	nd th	e dos	e of	grov	vth ł	norm	one l	being		
	reduc	ed if	IGF-1	excee	ds the	e nori	mal rai	nge o	f the	e re	fere	ncing	labo	orator	y foi	age	or p	uber	tal s	tage?)	
	Ye	S	N	lo																		
5.							i.e., int							oliosis	s pro	gres	sion	, slipp	oed o	capita	al	
					E], ne	eopla	sia, etc	.) fro	m th	ne r	nedi	catio	n?									
	Ye	S	N	О																		
(Fo	rm con	ntinu	ied on	next p	age.))																

© 2016–2021, Magellan Health, Inc. All rights reserved.

Magellan Rx Management – Commercial Clients Revision Date: 01/01/2021 Page 3 of 4

MHID: MRXCOM03_01

Prior Authorization Form: Growth Hormone

Member's Last Name:										ſ	Member's First Name:												
Fo	For Adult Members:																						
	 Has the member been evaluated for other endocrine disorders? Yes No 																						
	 Is the member receiving adequate replacement therapy for any other pituitary hormone deficiencies? Yes No 																						
	For Documented Childhood Onset GH Deficiency:																						
3.	3. Has the member failed the stimulation test? Yes No																						
Fo	For Adult Members Renewal:																						
1.	 Is serum insulin-like growth factor (IGF-1) being monitored and the dose of growth hormone being reduced if IGF-1 exceeds the normal range of the referencing laboratory? Yes 																						
2.	 Z. Does the member have toxicity (e.g., intracranial hypertension, scoliosis progression, slipped capital femoral epiphysis [SCFE], neoplasia) from the medication? Yes No 																						
3.	3. Has the member shown beneficial response to treatment evidenced by improvement in quality of life based on Quality of Life In Adult Growth Hormone Deficiency Assessment (QoL-AGHDA) or objective improvements in biochemistry, body composition, or bone mineral density? Yes No																						
tha	Attestation : I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.																						
																-	_						
Pre	Prescriber Signature (Required)											Date											
(Ву	signo	ature	, the P	hysici	noo ng	nfirm.	s the	? abo	ove ii	nfor	mat	tion	is ac	cura	te an	d vei	rifial	ole by	/ pati	ent r	ecor	ds.)	
Fax	this	form	to: 1-	800-4	24-32	60																	
Ma c/o 480 Pho	Mail requests to: Magellan Rx Management Prior Authorization Program c/o Magellan Health, Inc. 4801 E. Washington Street Phoenix, AZ 85034 Phone: 1-800-424-3312																						

© 2016–2021, Magellan Health, Inc. All rights reserved.

Magellan Rx Management – Commercial Clients Revision Date: 01/01/2021 Page 4 of 4